Portal de Periódicos da CAPES

Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development

2016; Mary Ann Liebert, Inc.; Volume: 2; Issue: 2 Linguagem: Inglês

10.1089/aivt.2016.0002

2332-1539

João Ribas, H. Sadeghi, Amir Manbachi, Jeroen Leijten, Katelyn N. Brinegar, Yu Shrike Zhang, Lino Ferreira, Ali Khademhosseini,

Neuroscience and Neural Engineering

Cardiovascular diseases are prevalent worldwide and are the most frequent causes of death in the United States. Although spending in drug discovery/development has increased, the amount of drug approvals has seen a progressive decline. Particularly, adverse side effects to the heart and general vasculature have become common causes for preclinical project closures, and preclinical models do not fully recapitulate human